期刊文献+

端粒酶活性与癌胚抗原诊断恶性腹水114例对比分析 被引量:6

The comparison on the value of diagnosis in malignant ascites between telomerase activity and CEA
下载PDF
导出
摘要 目的:比较端粒酶活性(TA)和癌胚抗原(CEA)指标诊断恶性腹水的价值。方法:良、恶性腹水各57例,应用端粒重复序列扩增-杂交-酶联免疫分析技术检测TA、磁性抗体分离酶联免疫测定技术检测CEA。比较TA与CEA诊断恶性腹水的特异性、敏感性、预测值、准确性等指标的差别。结果:腹水标本检测TA与CEA的阳性结果:恶性腹水组分别为48例(84.2%)与33例(57.9%)、良性腹水组分别为:4例(7.0%)与6例(10.5%),组间各指标阳性结果均具有极显著性差异(P<0.01)。TA与CEA诊断恶性腹水的特异性、敏感性、阳性预测值、阴性预测值、准确性分别为:93%与89.5%,84.2%与57.9%,92.3%与84.6%,91.4%与57.9%,87%与73.7%。结论:TA是良好的诊断恶性腹水指标,其诊断价值高于CEA。 Objective: To compare the value of diagnosis between telomerase activity (TA) and CEA in diagnosing malignant ascites. Methods: Telomeroc repeat amplification protocol- hybridismenzyme-linked immunosorbent assay (TRAP-Hyb-ELISA) and magnetic antibody immunoenzymetric assay (MAIA) were used to detect TA and CEA in 57 cases of malignant ascites (malignant group) and 57 cases of benign ascites (benign group), The difference of the value between TA and CEA in the diagnosis of malignant ascites was analysed. Results: The positive results of TA and CEA were 48(84.2%) and 33 (57.9%) in malignant group and 4(7.0%) and 6(10. 5%) in benign group. The difference between the two groups bad statistical meaning (P〈0. 001). The specificities, sensitivities, positive predictive values, negative predictive values and accuracies of TA and CEA were 93% and 89.5%, 84.2% and 57.9%, 92. 3% and 84. 6%, 91. 4% and 57. 9% and 87% and 73. 7%. Conclusion: TA is a useful index for the diagnosis of malignant ascites and its value is higher than CEA.
出处 《陕西医学杂志》 CAS 北大核心 2005年第9期1132-1134,共3页 Shaanxi Medical Journal
关键词 腹水/诊断 端粒末端转移酶/诊断应用 癌胚抗原/诊断应用 对比研究 癌胚抗原(CEA) 恶性腹水 抗原诊断 端粒酶活性 对比分析 端粒重复序列扩增 Ascites/diagnosis Telomerase/ diagnostic use Carcinoembryonic antigen/diagnostic use Comparative study
  • 相关文献

参考文献8

二级参考文献44

  • 1郑晓飞 孙克贤.端粒酶活性检测及其在恶性肿瘤诊断中的应用[M].北京:军事医学科学出版社,1997.49-56.
  • 2[1]De Lange T. Activation of telomerase in a human tumor[J]. Proc Natl Acad Sci USA 1994, 91: 2882-2885.
  • 3[2]Greider CW, Blackhum EH. Atelometic sequence in the RNA of tet rahymena telomerase required ofr telomererepeat synthesis[J]. Nature (Lood), 1989, 337: 331-337.
  • 4[3]Kim NW, Piatyszid MA, Prowse KR, et al. SPecific association of human telomerase activity with immortal cells and cancer[J]. Science,1994, 266: 2011-2015.
  • 5[4]Taharh H, Nakanishi T, Kitamoto M, et al. Telomerase activity in human liver tissues: comparison between chonic liver disease and hcpatocellular carcinomas[J ]. Cancer Res, 1995, 55: 2734-2738.
  • 6[5]Himaya E, Yokoyama T, Tastsuumoto N, et al. Telomerase activityin gastric cancer[J]. Cancer Research, 1995, 55:3258-3263.
  • 7[6]EngelhardtM, Langenfeld J, HanW, et al. High telmeraseactivityin primary lung cancrs: association with increased cell proliferation rates and advanced pathologic stage[J]. J Nat Cancer Inst, 1997, 89: 11609-1615.
  • 8[7]AhnMJ, Noh YH, Lee YS, et al. Telomerase activity and its clinico pathological significan-ce in gastric cancer[J]. EurJ Cancer, 1997,33:1309-1312.
  • 9[1]Kim NW, Piatyszek MA, Prowse KR, et al. Specific associa tion of human telomerase activity with immortal cells and cancer. Science, 1994, 266(5193): 2011~2015
  • 10[2]Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer, 1997, 33(5):781~786

共引文献39

同被引文献39

引证文献6

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部